Milestone Pharmaceuticals: Positioned for Success with Cardamyst’s Potential Approval and Launch
Analyst Brandon Folkes from H.C. Wainwright maintains a Buy rating on Milestone Pharmaceuticals with a price target of $5.00, driven by the potential approval of Cardamyst, a nasal spray for PSVT, expected in December 2025. The product is positioned as a first-to-market therapy that could enhance patient care. Milestone has improved its financial standing and resolved prior regulatory issues, leading to FDA acceptance of their NDA. This positions the company for significant stock performance, especially with the promising AFib-RVR program.
Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals and keeping the price target at $5.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Brandon Folkes has given his Buy rating due to a combination of factors, primarily centered around the potential approval and launch of Cardamyst, a nasal spray for paroxysmal supraventricular tachycardia (PSVT). The anticipated approval in December 2025 positions Cardamyst as a first-to-market, at-home therapy that could significantly transform patient care and reduce healthcare burdens. Additionally, Milestone Pharmaceuticals has strengthened its financial position, providing the necessary resources to support a successful product launch.
Moreover, the company has addressed previous regulatory concerns, leading to the FDA’s acceptance of their resubmitted NDA. This swift resolution indicates that the issues were manageable and unlikely to impede the December approval. The potential for Cardamyst to outperform market expectations, coupled with the promising AFib-RVR program, suggests that Milestone Pharmaceuticals’ stock could significantly outperform its peers in the coming years.
According to TipRanks, Folkes is an analyst with an average return of -1.2% and a 40.33% success rate. Folkes covers the Healthcare sector, focusing on stocks such as MannKind, Eupraxia Pharmaceuticals, and Achieve Life Sciences.
